Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction

Abstract

Introduction: Tiotropium Respimat® add-on therapy is well tolerated and improves lung function in children with persistent asthma despite inhaled corticosteroid (ICS) treatment ± other controllers. Aims and Objectives: To determine whether this efficacy varies in children with moderate persistent asthma with different degrees of airflow obstruction. Methods: CanoTinA-asthma® (NCT01634139) was a Phase III, randomised, double-blind, placebo-controlled 48-week trial in children (6–11y) with moderate persistent asthma. Patients received once-daily tiotropium Respimat® 5 or 2.5 µg (as 2 puffs) or placebo, as add-on to at least ICS. This post hoc analysis stratified patients by FEV1 % predicted at screening (80– Results: 401 patients were treated. Baseline characteristics were balanced between treatment arms. At Week 24, tiotropium Respimat® add-on therapy improved peak and trough FEV1 responses (Table 1) and FEF25–75% response vs. placebo, independent of FEV1 % predicted at screening. Conclusion: In children (6–11y) with moderate symptomatic asthma, once-daily tiotropium Respimat® add-on therapy improves lung function compared with placebo, irrespective of the degree of airflow obstruction at screening.